GlassScriptPhysician profile
Amanda L Murray
NPI 1366968141
$1,825.67
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $125 · 2023: $738 · 2024: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $951.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $622.78 | 2021-2024 | |
| Sk Life Science, INC. | $215.58 | 2023-2024 | Xcopri |
| Greenwich Biosciences, INC. | $180.91 | 2021 | |
| Livanova USA, INC. | $172.57 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $126.14 | 2023 | Andexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Abbvie INC. | $122.39 | 2023 | |
| Relievant Medsystems, INC. | $87.59 | 2023 | Intracept |
| Genentech USA, INC. | $46.33 | 2024 | Xolair |
| Boston Scientific Corporation | $30.11 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $28.97 | 2021 | |
| Eisai INC. | $21.15 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.27 | 2021 | |
| Ucb, INC. | $16.22 | 2021 | |
| Biogen, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.